Minocycline treatment prevents cavitation in rats after a cortical devascularizing lesion

被引:19
作者
Hua, Rui [1 ]
Walz, Wolfgang [1 ]
机构
[1] Univ Saskatchewan, Dept Physiol, Saskatoon, SK S7N 5E5, Canada
关键词
minocycline; ischemia; stroke; microglia; astrocytes; reactive gliosis;
D O I
10.1016/j.brainres.2006.03.072
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Minocycline, a second-generation tetracycline, has been shown to possess neuroprotective effects in animal models of stroke. Pial vessel disruption in adult Wistar rats leads to a cone-shaped cortical lesion and turns into a fluid-filled cavity surrounded by a GFAP+ glia limitans 21 days after injury. This mimics the clinical situation in lacunar infarcts. Minocycline was given intraperitoneally at a dose of 4S mg/kg 1 and 12 h after lesioning, followed by 22.S mg/kg twice daily until 6 days after lesioning. Control rats received intraperitoneal injections of equivalent volumes of saline. Cavitation was prevented in five out of six minocycline-treated animals and the glia limitans did not appear as the space was filled with GFAP+ reactive astrocytes. However, the number of activated microglia showed no difference between minocycline-treated and -untreated groups. Minocycline did not reduce the number of infiltrating leukocytes, predominately polymorphonuclear neutrophils (PMNs) determined by myeloperoxidase immunoreactivity, or infiltration of CD3+ lymphocytes. The pial vessel occlusion induced a significant upregulation of IL-1 beta expression; however, minocycline treatment did not significantly alter this upregulation of IL-1 beta. In this study, we found minocycline facilitated the repopulation of the lesion by reactive astrocytes and therefore prevented cavitation; however, we could not identify the molecular signal. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:172 / 181
页数:10
相关论文
共 49 条
[1]   New concepts in lacunar stroke etiology:: The constellation of small-vessel arterial disease [J].
Arboix, A ;
MartíVilalta, JL .
CEREBROVASCULAR DISEASES, 2004, 17 :58-62
[2]   Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury [J].
Arvin, KL ;
Han, BH ;
Du, YS ;
Lin, SZ ;
Paul, SM ;
Holtzman, DM .
ANNALS OF NEUROLOGY, 2002, 52 (01) :54-61
[3]  
Bar T., 1980, ADV ANAT EMBRYOL CEL, V59, P1, DOI DOI 10.1007/978-3-642-67432-7_1
[4]   Formalin-fixed and heat-retrieved tissue antigens: A comparison of their immunoreactivity in experimental antibody diluents [J].
Boenisch, T .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2001, 9 (02) :176-179
[5]   Targeting leukocyte MMPs and transmigration - Minocycline as a potential therapy for multiple sclerosis [J].
Brundula, V ;
Rewcastle, NB ;
Metz, LM ;
Bernard, CC ;
Yong, VW .
BRAIN, 2002, 125 :1297-1308
[6]   Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease [J].
Chen, M ;
Ona, VO ;
Li, MW ;
Ferrante, RJ ;
Fink, KB ;
Zhu, S ;
Bian, J ;
Guo, L ;
Farrell, LA ;
Hersch, SM ;
Hobbs, W ;
Vonsattel, JP ;
Cha, JHJ ;
Friedlander, RM .
NATURE MEDICINE, 2000, 6 (07) :797-+
[7]   Rise and fall of minocycline in neuroprotection: need to promote publication of negative results [J].
Diguet, E ;
Gross, CE ;
Tison, F ;
Bezard, E .
EXPERIMENTAL NEUROLOGY, 2004, 189 (01) :1-4
[8]   Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease [J].
Diguet, E ;
Fernagut, PO ;
Wei, X ;
Du, YS ;
Rouland, R ;
Gross, C ;
Bezard, E ;
Tison, F .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2004, 19 (12) :3266-3276
[9]   Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease [J].
Diguet, E ;
Rouland, R ;
Tison, F .
ANNALS OF NEUROLOGY, 2003, 54 (06) :841-842
[10]   Neuroprotection by tetracyclines [J].
Domercq, M ;
Matute, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (12) :609-612